SQA
ICPT

Simon Quick Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Simon Quick Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2
Closed -$159 – 552
2019
Q2 		$159 Buy
+2
New +$179 ﹤0.01% 465

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Simon Quick Advisors's ICPT Position: Q3 2019 in Review

Simon Quick Advisors sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2019, closing a stake of 2 shares — an estimated $159 sold.

Simon Quick Advisors first reported a position in ICPT in Q2 2019 and held it in 1 quarter. The position peaked at $159 in Q2 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q3 2019.

  • Simon Quick Advisors reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Simon Quick Advisors sold 2 Intercept Pharmaceuticals, Inc. shares in Q3 2019, an estimated $159.
  • Simon Quick Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Simon Quick Advisors's Intercept Pharmaceuticals, Inc. position peaked at $159 in Q2 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2019.

Based on Simon Quick Advisors's 13F filing for Q3 2019, filed 16 Oct 2019.